Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Orthopedics, Musculoskeletal & Joint Replacement (Pharmaceuticals, Diagnostics & Biotechnology)

BioMimetic Therapeutics

Parents

*Architects: Biomaterials (Growth Factors)
*Architects: Orthopedics, Musculoskeletal & Joint Replacement (Pharmaceuticals, Diagnostics & Biotechnology)
*Architects: Regenerative Medicine
*ARMi-Alliance for Regenerative Medicine-International: Industrial Partners
*Portfolio Companies: PTV
Companies: Acquired_(M&A)

*Portfolio Companies: MB Ventures
2013: Wright finalizes $190M-plus BioMimetic buy (2013)
60 employees (2006)
BioMimetic has a marketing agreement with privately held Luitpold Pharmaceuticals to sell GEM 21S worldwide
BioMimetic puts the global market for those conditions at $9.8 billion.
BioMimetic puts the potential U.S. market at $700 million
BioMimetic's suite of products and product candidates combine recombinant protein therapeutics with tissue specific scaffolds, a
Combines genetically engineered proteins with a synthetic matrix to stimulate bone and tissue healing and regeneration
Development and commercialization of drug-device combination products for the repair of orthopedic injuries to bone, cartilage,
First product, GEM 21S, treats periodontal bone defects and receding gum tissue
Founded 2009
Franklin, Tennessee
Samuel Lynch. He serves as chief executive and president, BioMimetic
The company has similar biodevice projects under way for wrist, foot and ankle fractures, spinal fusions, tendon and ligament re